Dementia Flashcards

1
Q

Describe the clinical features of Alzheimer’s disease.

A

Alzheimer’s disease is the most common form dementia characterized by cerebral cortex atrophy, formation of amyloid ‘plaques’ and neurofillary ‘tangles’, decreased ACh production, and progressive damage to the brain over time.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What are the risk factors associated with dementia?

A

Risk factors for dementia include age, mild cognitive impairment, genetics, cardiovascular disease risk factors like diabetes and hypertension, Parkinson’s disease, stroke, depression, heavy alcohol consumption, and low educational attainment.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Define mild cognitive impairment (MCI) how it differs from dementia.

A

MCI does not meet the diagnostic criteria for dementia as it may only affect one cognitive domain or not significantly impact daily activities, unlike dementia which involves deteriorating mental function interfering with daily living.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

How does vascular dementia differ from Alzheimer’s disease in terms of its cause?

A

Vascular dementia is caused by problems in blood supply to the brain, often due to strokes, while Alzheimer’s disease is a physical disease resulting from changes in brain structure and chemical shortages affecting message transmission.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Describe the subtypes of dementia other than Alzheimer’s disease and vascular dementia.

A

Other subtypes include mixed dementia (both Alzheimer’s and vascular), dementia with Lewy bodies (irregular brain cell function), and rarer causes like Corticobasal degeneration and Creutzfeldt-Jakob disease.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

How do the clinical features of dementia typically progress over time?

A

Dementia symptoms progress with time, starting with insidious onset and non-specific signs, advancing through early, middle, and late stages, with symptoms varying from person to person and becoming more severe as damage to the brain increases.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Describe the progression of symptoms in the early stage of dementia.

A

In the early stage of dementia, individuals may become forgetful, have difficulty with communication, get lost in familiar places, lose track of time struggle with decision-making and handling finances, experience mood changes like depression and anxiety, and show interest in hobbies.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What are some common symptoms in the middle stage of dementia?

A

In the middle stage of dementia, individuals may exhibit very forgetful behavior, have trouble comprehending time and events, struggle with communication and personal care, be unable to prepare food or live alone safely, and may display behavioral changes like wandering, repeated questioning, and hallucinations.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

How does dementia typically progress in the late stage?

A

In the late stage of dementia, individuals are usually unaware of time and place, have difficulty understanding their surroundings, cannot recognize relatives or familiar objects, struggle to eat without assistance, experience incontinence, changes in mobility, and may exhibit aggression or non-verbal agitation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Define the prognosis of dementia as a life-limiting condition.

A

Dementia is a life-limiting condition with no cure, where the length of time between diagnosis and death varies. Factors like age at onset, gender, and dementia subtype can influence median survival, which is typically 3-9 years after diagnosis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What are the key steps involved in diagnosing dementia?

A

Diagnosing dementia involves obtaining a history from the patient and informant, assessing cognitive, behavioral, and psychological symptoms, evaluating the impact on daily life, reviewing comorbidities and risk factors, conducting physical examinations, blood and urine tests, cognitive testing, and referring to specialist dementia diagnostic services.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Describe the behavioral changes that may occur in individuals with dementia.

A

Individuals with dementia may exhibit behavioral changes such as mood swings, aggression, disinhibition, wandering, disturbed sleep, hallucinations, inappropriate behavior in the home or community, and aggression towards caregivers as the condition progresses through its stages.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Describe the Mini-Cog assessment process for dementia. What are the steps involved and what is the purpose each step?

A

The Mini-Cog assessment for dementia involves three steps: 1) Three-word recognition to test immediate memory, 2) Clock drawing to assess visuospatial abilities, and 3) Word recall to evaluate delayed memory. The purpose is to screen for cognitive impairment.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

How can cognitive symptoms in patients with mild-to-moderate dementia be managed non-pharmacologically? Provide examples of interventions.

A

Cognitive symptoms in mild-to-moderate dementia can be managed non-pharmacologically through structured group cognitive stimulation programs, group reminiscence therapy, and cognitive rehabilitation or occupational therapy. These interventions aim to improve cognition and overall well-being.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Define acetylcholinesterase inhibitors (AChIs) in the context of dementia treatment. What benefits do they offer and what are some common cautions associated with their use?

A

Acetylcholinesterase inhibitors (AChIs) are drugs that block the degradation of acetylcholine, providing modest benefits in cognition, function, and behavior in patients with mild-to-moderate Alzheimer’s disease. Common cautions include issues like COPD, asthma, and cardiac abnormalities.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What is the role of Donepezil hydrochloride in dementia treatment? Describe its dosing regimen, common side effects, and metabolism pathway.

A

Donepezil hydrochloride is a reversible inhibitor of acetylcholinesterase used in dementia treatment. It is dosed at 5mg once daily for one month, then increased to 10mg daily if needed, metabolized by the cytochrome P450 system. Common side effects include diarrhea, muscle cramps, and fatigue.

17
Q

Describe the goals of dementia care. What are the key objectives in managing dementia patients effectively?

A

The goals of dementia care include early diagnosis for optimal management, optimizing physical health and cognition, identifying and treating accompanying physical illnesses, managing challenging behaviors, and providing support to caregivers. The focus is on promoting overall well-being and quality of life.

18
Q

How can cognitive symptoms in dementia be managed pharmacologically? What are some common pharmacological treatments used and how are they administered?

A

Cognitive symptoms in dementia can be managed pharmacologically with drugs like acetylcholinesterase inhibitors (AChIs) such as Donepezil, Galantamine, Rivastigmine, and Memantine. These drugs are initiated and supervised by specialists, with dosing adjustments based on symptom response and tolerability.

19
Q

Describe the pharmacological properties of galantamine and its dosing regimen. What are the key warnings associated with its use?

A

Galantamine is a reversible inhibitor of acetylcholinesterase with nicotinic receptor agonist properties. It is dosed twice daily but less tolerated than other AChE inhibitors. Patients should be warned about signs of serious skin reactions. It is metabolized by the cytochrome P450 system.

20
Q

What are the characteristics of rivastigmine as an acetylcholinesterase inhibitor? How does it differ from other AChE inhibitors in terms of metabolism and side effect reduction?

A

Rivastigmine is a reversible non-competitive inhibitor of acetylcholinesterase that also inhibits butyrylcholinesterase. It is metabolized by the liver and side effects can be reduced using a transdermal patch. It is also licensed for mild-to-moderate dementia in Parkinson’s disease.

21
Q

How does memantine hydrochloride function in the treatment of Alzheimer’s disease? What is its dosing regimen and common side effects?

A

Memantine hydrochloride is a glutamate receptor antagonist that blocks excitotoxic neuronal toxicity associated with excessive release of glutamate. It is licensed for moderate-to-severe Alzheimer’s disease with a dosing regimen starting at 5mg once daily and increasing weekly to a max of 20mg daily. Common side effects include dizziness, headache, constipation, somnolence, and hypertension.

22
Q

Define the treatment conditions for initiating AChE inhibitors or memantine in patients with dementia. What considerations should be taken into account before prescribing these medications?

A

Initiate treatment on advice of a clinician with necessary knowledge and skills. The first prescription may be made in primary care once the decision is made to start AChE inhibitors or memantine. Local arrangements for prescribing, supply, and treatment review should be ensured. AChE inhibitors should not be stopped solely based on disease severity.

23
Q

How should non-cognitive symptoms in patients with dementia be managed pharmacologically? When is drug treatment recommended, and what should be avoided in patients with mild-to-moderate symptoms?

A

Non-cognitive symptoms like delusions or aggression should be assessed for reversible causes. Non-pharmacological interventions may be beneficial. Drug treatment should only be offered if the patient is at risk of harm or severe distress. Mild-to-moderate symptoms should not be treated with antipsychotic drugs.

24
Q

What are the considerations for using antipsychotic drugs in patients with severe non-cognitive symptoms in dementia? How should treatment be initiated and monitored to minimize risks?

A

Antipsychotic drugs should be carefully considered for patients with severe non-cognitive symptoms causing distress. Co-morbid conditions and benefits/risks of treatment should be evaluated. Treatment should start at a low dose, titrated upwards with regular review, and used for the shortest possible time to minimize risks like stroke and increased mortality.

25
Q

Describe the impact of anticholinergic burden on mortality rates and the various considerations related to managing it in older adults.

A

Anticholinergic burden (ACB) in older adults is linked to higher mortality rates. Managing ACB involves addressing co-morbidities, driving concerns, medication adherence, caregiver health, and future planning like advance directives and end-of-life care.

26
Q

Define the concept of polypharmacy and its impact on older adults’ cognitive health. How can healthcare professionals address polypharmacy-related cognitive issues in the elderly population?

A

Polypharmacy refers to the simultaneous use of multiple medications. It can negatively impact cognitive health in older adults. Healthcare professionals can address polypharmacy-related cognitive issues by reviewing medications, identifying potential contributors to cognitive problems, and recommending alternative treatments to reduce the cognitive burden.

27
Q

Discuss the importance of considering mental and physical health when caring for older adults taking multiple medications. How can caregivers support older individuals in managing their medication regimens effectively?

A

Caregivers need to prioritize the mental and physical well-being of older adults on multiple medications. They can support medication management by ensuring adherence, monitoring for side effects, and coordinating with healthcare providers to address any concerns promptly.